Why the hours on the machine matter more than the label on the trial arm
CPAP only treats sleep apnea while the mask is on and the airway is kept open. A trial that compares “active” with “sham” CPAP by intention to treat averages everyone in each arm, including people who barely use the device. That dilutes any real biological effect. In the Diabetes Sleep Treatment Trial, the active and sham groups had similar HbA1c reductions at 12 weeks, but within the data, more cumulative hours of CPAP use and a higher percentage of days with at least 4 hours of use were associated with greater HbA1c improvement [1]. The same pattern appeared for a threshold: using CPAP at least 7 hours was associated with a significant HbA1c reduction [1].
This is an association, not proof that hours cause the improvement. People who use CPAP more may also differ in other ways—better sleep habits, more consistent routines, or more severe apnea at baseline—that could influence blood sugar. Still, the dose-response pattern is consistent with a real effect of nightly use rather than a simple on/off benefit of being assigned to active treatment.
What continuous glucose monitoring adds—and what it does not settle
A separate study using continuous glucose monitoring for two weeks found that patients on CPAP had significantly lower postprandial and fasting glucose, lower HbA1c, and less glucose fluctuation than controls [2]. The CPAP group in that study used the machine for an average of 8.3 hours per night, which is well above the usual adherence threshold [2]. That high average use is important: it means the study mainly tells us what happens when people actually wear CPAP for most of the night, not whether assignment alone helps.
That study did not compare adherence hours against treatment assignment directly [2]. So it supports the idea that CPAP can improve glucose stability when used consistently, but it does not by itself prove that hours matter more than the randomized group.
In real-world use, adherence predicts blood pressure better than HbA1c
A large retrospective study of 1,295 patients with type 2 diabetes and sleep apnea found that only about one in five was adherent to CPAP, defined as at least 4 hours per night on at least 70% of nights [4]. Adherent patients had significantly lower systolic and diastolic blood pressure than nonadherent patients, and among adherent patients, greater CPAP use was associated with lower systolic blood pressure [4]. However, HbA1c, lipids, kidney function, and cardiovascular events did not differ between adherent and nonadherent groups [4].
This is a useful reality check. It suggests that adherence may matter for some outcomes—blood pressure clearly—but that HbA1c improvement is not guaranteed even among people who meet the standard adherence threshold. The study was observational and looked at associations over about 2.5 years, so it cannot show that CPAP use caused the blood pressure difference or that it failed to cause an HbA1c difference [4].
When CPAP may not move blood sugar much at all
Not every study finds a glucose benefit. In a small three-month study of Japanese patients with type 2 diabetes starting CPAP, HbA1c did not change significantly in either the group taking an SGLT2 inhibitor or the group taking other diabetes drugs [5]. That study did not report or analyze nightly adherence hours, so it cannot tell us whether poor adherence explained the lack of effect [5]. It does show that CPAP is not a reliable glucose-lowering treatment on its own, at least over a few months and in a small sample.
The systematic review that examined twelve studies found that most reported positive effects on glycemic control, but some showed non-significant or limited improvements, and it highlighted adherence as a crucial factor [3]. Taken together, the evidence suggests that CPAP is more likely to help blood sugar when people use it consistently for most of the night—but the effect is modest and not guaranteed, and it may be smaller than the effect on blood pressure.
Sources used in this answer
Effect of Treatment of OSA With CPAP on Glycemic Control in Adults With Type 2 Diabetes: The Diabetes Sleep Treatment Trial (DSTT)
In a 12-week randomized trial, active and sham CPAP produced similar average HbA1c changes, but greater cumulative CPAP use and more nights with at least 4 hours were associated with larger HbA1c reductions, and use of at least 7 hours was associated with a significant HbA1c reduction.
Effect of CPAP on blood glucose fluctuation in patients with type 2 diabetes mellitus and obstructive sleep apnea
In a two-week continuous glucose monitoring study, patients using CPAP for an average of 8.3 hours per night had significantly lower postprandial and fasting glucose, lower HbA1c, and less glucose fluctuation than controls.
Systematic Review of The Effect Of CPAP Therapy on Glycemic Control in Patients with Obstructive Sleep Apnea and Type 2 Diabetes
A systematic review of twelve studies found that most reported positive effects of CPAP on glycemic control, but some showed limited or non-significant effects, and adherence emerged as a crucial factor.
Association of continuous positive airway pressure adherence with complications in patients with type 2 diabetes and obstructive sleep apnea
In a retrospective study of 1,295 patients, CPAP adherence was associated with significantly lower blood pressure, but HbA1c, lipids, kidney function, and cardiovascular events did not differ between adherent and nonadherent groups.
Effect of Treatment With Sodium-Glucose Cotransporter 2 Inhibitor on the Initiation of Continuous Positive Airway Pressure Therapy in Type 2 Diabetic Patients With Obstructive Sleep Apnea Syndrome
In a small three-month study, HbA1c did not change significantly after starting CPAP in either patients taking an SGLT2 inhibitor or those taking other diabetes drugs.